Home » Topics » BioWorld Science

BioWorld Science
RSS

Topline data from phase I study of NASH drug candidate ASC-42

June 17, 2021

Mydecine launches in silico drug discovery program with University of Alberta

June 17, 2021

DSMB recommends phase I trial of rhenium nanoliposomes in GBM proceed to next cohort

June 17, 2021

Phase I/II trial of eprenetapopt in TP53-mutant AML meets primary efficacy endpoint

June 17, 2021

Safety data presented for BGB-11417 in R/R B-cell malignancies

June 17, 2021

MacroGenics and Zai Lab collaborate on bispecific molecules in immuno-oncology

June 17, 2021

Paratek opens phase IIb study of Nuzyra in M. abscessus pulmonary disease

June 17, 2021

Switching on prodrugs with radiotherapy shows promise

June 17, 2021

Second patient dosed in phase I/II MARVEL-1 study of FLT-190 in Fabry disease

June 17, 2021

Preclinical data for NVG-111: a ROR1xCD3 bispecific antibody

June 17, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 7, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.